Exhibit 99.1            

    
                                        
    
COMPANY CONTACTS:
INVESTOR CONTACTS:
Endologix, Inc.
The Ruth Group
John McDermott, CEO
Nick Laudico (646) 536-7030
Vaseem Mahboob, CFO
Zack Kubow (646) 536-7020
(949) 595-7200
 
www.endologix.com
 
                
Endologix Reports Results for the Fourth Quarter and Full Year 2015

8% Constant Currency Revenue Growth for the Full Year 2015

2015 Nellix European Systems Increase 42% Over Prior Year

Provides 2016 Financial Guidance for Combined Company Following Completion of Merger with TriVascular Technologies, Inc. on February 3, 2016


IRVINE, Calif., February 22, 2016 - Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve

months ended December 31, 2015.

John McDermott, Endologix Chairman and Chief Executive Officer, said, “We are entering 2016 with positive momentum for all of the key growth drivers in our business, highlighted by completion of our merger with TriVascular in early February. The combined company is uniquely positioned in the market with the broadest AAA product portfolio; an experienced and expanded sales force; and several upcoming new product launches. For the full year 2015 in Europe, Nellix system sales were up 42% and the data from the Global Registry continues to be positive, confirming the clinical benefits achieved with endovascular aneurysm sealing. In the U.S., our PMA timeline for Nellix remains unchanged, positioning us for potential FDA approval in late 2016 or the first quarter 2017.”

Financial Results

Global revenue in the fourth quarter of 2015 was $39.2 million, a 1% increase from $38.8 million in the fourth quarter of 2014. These results were impacted by strong distributor sales in the fourth quarter of 2014 and anticipated merger related disruption in the fourth quarter of 2015. For the year ended December 31, 2015, global revenue increased 4% to $153.6 million, compared to $147.6 million for the year ended December 31, 2014. On a constant currency basis, revenue for the fourth quarter and full year ended December 31, 2015 increased 4% and 8%, respectively.

U.S. revenue in the fourth quarter of 2015 was $26.4 million, down slightly from $27.0 million in the fourth quarter of 2014 due to the temporary delay in patient enrollment in the Nellix Continued Access Program, or CAP, and anticipated sales force disruption related to Endologix’s merger with TriVascular. Excluding the impact of the CAP, U.S. fourth quarter revenue remained flat compared to 2014. International revenue was $12.8 million, an 8% increase compared to $11.8 million in the fourth quarter of 2014. On a constant currency basis, fourth quarter international revenue increased 17%. European revenue was $8.2 million, a 5% increase as compared to $7.8 million in the fourth quarter of 2014, representing 18% growth on a constant currency basis. Nellix system sales increased 18% in Europe in the fourth quarter of 2015 compared to the fourth quarter of 2014, which reflects higher Nellix distributor sales in 2014 and a 49% increase in the Company's European direct business in the fourth quarter of 2015.

Gross profit was $23.7 million in the fourth quarter of 2015, which represents a gross margin of 60%, compared to gross margin of 76% in the fourth quarter of 2014. Gross profit was $101.8 million for the year ended December 31, 2015, which represents a gross margin of 66%, compared to gross margin of 72% for the year ended December 31, 2014. The decrease in gross margin for the fourth quarter was primarily due to inventory write-offs of $3.4 million for product transitions and an increase in the Company's obsolete inventory reserve as result of quality and process improvements. Inventory write-offs were $7.9 million for the full year of 2015.

Total operating expenses were $45.5 million in the fourth quarter of 2015, compared to $40.5 million in the fourth quarter of 2014. Fourth quarter 2015 operating expenses included a $1.9 million contract termination for Endologix's former Japanese distributor and $3.2 million for business acquisition expenses related to the Trivascular merger. Total operating expenses for the year ended December 31, 2015 were $154.7 million, compared with $134.9 million for the year ended December 31, 2014. The increase in operating expenses for the year ended December 31, 2015 was driven primarily by the expansion of sales and clinical personnel in Europe; increased research, development, clinical and regulatory expenses; and the contract termination and business acquisition expenses referenced above.

Net loss for the fourth quarter of 2015 was $15.3 million or $(0.22) per share, compared with net loss of $14.8 million, or $(0.22) per share, for the fourth quarter of 2014. Endologix reported a negative Adjusted EBITDA (non-GAAP and defined below) for the fourth quarter of 2015 of $11.5 million, or $(0.17) per share, compared with a negative Adjusted EBITDA for the fourth quarter of 2014 of $3.4 million, or $(0.05) per share.

For the year ended December 31, 2015, net loss was $50.4 million, or $(0.75) per share, compared to a net loss of $32.4 million, or $(0.50) per share, for the year ended December 31, 2014. Negative Adjusted EBITDA (non-GAAP and defined below) for the year ended December 31, 2015 was $30.0 million, or $(0.44) per share, compared with a negative Adjusted EBITDA (non-GAAP and defined below) for the year ended December 31, 2014 of $13.7 million, or $(0.21) per share.

For the twelve months ended December 31, 2015, provision for income taxes was a benefit of $9.3 million due to the recognition of a deferred tax liability of $9.6 million as a result of the temporary difference between the carrying value and the tax basis of the convertible senior notes sold by the Company in November 2015. This liability resulted in a reduction of the Company's valuation allowance which was recorded as a benefit to income tax expense in 2015.

Total cash, cash equivalents and marketable securities were $177.3 million as of December 31, 2015, compared to $86.7 million as of December 31, 2014. In November, the Company raised $121.4 million in net proceeds from the sale of convertible senior notes in an underwritten public offering, a portion of which was used to repay certain outstanding indebtedness of Trivascular in conjunction with the closing of Endologix’s merger with TriVascular.





Financial Guidance

Endologix anticipates 2016 revenue for the combined company to be in the range of $192 million to $202 million, representing growth of 1% to 6% compared to the pro-forma combined revenue results of Endologix and Trivascular in 2015. Endologix anticipates 2016 GAAP loss per share of $(1.20) to $(1.30) per share and 2016 Adjusted loss per share (non-GAAP and defined below) of $(0.70) to $(0.80) per share. This guidance excludes purchase price accounting impact related to Trivascular merger.

Conference Call Information

Endologix's management will host a conference call today to discuss these topics beginning at 5:00 P.M. Eastern time (2:00 P.M. Pacific time). To participate via telephone please call (877) 407-0789 from the U.S. or 1-(201)-689-8562 from outside the U.S. A telephone replay will be available for seven days following the completion of the call by dialing (877) 870-5176 from the U.S. or 1-(858)-384-5517 from outside the U.S., and entering pin number 13629814. The conference call will be broadcast live over the Internet at www.endologix.com. After the live webcast, a webcast replay of the call and a transcript of the call will be available online from the investor relations page of Endologix's website through February 22, 2017.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

The Nellix® EndoVascular Aneurysm Sealing System has obtained CE Mark in the EU and is only approved as an investigational device in the United States.

Cautions Regarding Forward-Looking Statements

Except for historical information contained herein, this news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the benefits of the recently completed merger with Trivascular, anticipated growth opportunities, sales of, continued physician adoption of and interest in Nellix®, the progress of clinical trials, the results of clinical trials, our ability to obtain regulatory approval of our existing products and potential future products, our ability to increase revenue through sales of our existing products and potential future products, and 2016 financial guidance, the accuracy of which are necessarily subject to risks and uncertainties, that may cause Endologix’s actual results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ materially and adversely from anticipated results include our ability to integrate the business and realize the expected benefits of the recently completed merger with Trivascular, continued market acceptance, endorsement and use of Endologix' products, the success of clinical trials relating to Endologix’s products under development, product research and development efforts, uncertainty in the process of obtaining regulatory approval for Endologix's products, risks associated with international operations, including currency exchange rate fluctuations, Endologix’s ability to protect its intellectual property rights and proprietary technologies, and other economic, business, competitive and regulatory factors. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Endologix undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Endologix's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2014, for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.

Discussion of Non-GAAP Financial Measures

Endologix's management believes that the non-GAAP measures of (1) "Adjusted Net Income (Loss)", (2) "Adjusted Net Income (Loss) Per Share”, (3) “Adjusted EBITDA", and (4) "Adjusted EBITDA Per Share" enhance an investor's overall understanding of Endologix's financial and operating performance and its future prospects by (i) being more reflective of core operating performance and (ii) being more comparable with financial results over various periods. Endologix's management uses these financial measures for strategic decision making, forecasting future financial results, and evaluating current period financial and operating performance. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Share Definitions:

"GAAP" is generally accepted accounting principles in the United States.

(1) "Adjusted Net Income (Loss)" is a non-GAAP measure defined by Endologix as net income (loss) under GAAP, excluding: (i) the fair value adjustment to the Nellix acquisition contingent consideration; (ii) interest expense from the Company's convertible debt; (iii) foreign currency (gains) or losses; (iv) legal settlement costs; (v) contract termination and business acquisition expenses; and (vi) business development expenses, including licensing costs related to research and development activities.

In the three and twelve months ended December 31, 2015, this GAAP adjustment to net loss specifically represents: (i) the fair value adjustment to the Nellix acquisition contingent consideration liability; (ii) interest expense from the Company's convertible debt; (iii) foreign currency (gains) or losses; (iv) business development expenses; and (v) contract termination and business acquisition expenses.

In the three and twelve months ended December 31, 2014, this GAAP adjustment to net loss specifically represents: (i) the fair value adjustment to the Nellix acquisition contingent consideration liability; (ii) interest expense from the Company's convertible debt; and (iii) foreign currency (gains) or losses; and (iv) business development expenses.

In future periods, Adjusted Net Income (Loss) will continue to exclude: (i) the fair value adjustments to the Nellix contingent consideration liability; (ii) interest expense from the Company's convertible debt; (iii) foreign currency (gains) or losses; (iv) legal settlement costs; (v) contract termination and business acquisition expenses; (vi) business development expenses; and (vii) other non-recurring expenses or income, as described by Endologix.

(2) "Adjusted Net Income (Loss) per Share" is a non-GAAP measure defined by Endologix as Adjusted Net Income (Loss) divided by the average shares outstanding (basic and diluted, as applicable under GAAP) for the corresponding period.

Adjusted EBITDA and Adjusted EBITDA Per Share Definitions:

(3) “Adjusted EBITDA” is a non-GAAP measure defined by Endologix as “Adjusted Net Income (Loss)” plus income tax (benefit) expense, depreciation and amortization expense, and stock-based compensation expense.

(4) “Adjusted EBITDA per Share” is a non-GAAP measure defined by Endologix as Adjusted EBITDA divided by average shares outstanding (basic and diluted, as applicable under GAAP) for the corresponding period.

# # #



The following information was filed by Endologix Inc (ELGX) on Monday, February 22, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Endologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Endologix Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account